Savvyn
About Savvyn
Healthcare innovations stall not because the science is weak, but because evidence expectations are fragmented and inconsistent across payers. Teams generate strong evidence across many sources—yet still lack a clear view of what truly matters, which gaps will block coverage, or what actions will accelerate adoption.
Savvyn is building the evidence intelligence layer for healthcare innovation: a structured, transparent system that maps evidence to payer expectations and clarifies the pathway from validation to real-world impact. At the core is the Savvyn Intelligence Layer, which brings these signals together to translate complexity into clear guidance on what to do next.
Why Savvyn, and Why Now?
Savvyn was built around a hard-earned truth: strong science alone doesn’t guarantee patient impact. Even when innovations have meaningful clinical evidence, access depends on whether insurers are willing to cover them—and coverage expectations are often fragmented, inconsistent, or discovered too late.
For the first time, generative AI makes it possible to make those expectations visible and actionable—bringing structure to evidence decisions so teams can move faster from innovation to real-world impact.
Oncology First
Savvyn’s foundation is deep oncology expertise—decades of work across cancer biology, diagnostics, evidence generation, and payer strategy. Oncology is the natural first vertical because evidence requirements are more complex, payer variation is more consequential, and the gap between clinical validation and clinical access is often the widest.
What We Believe
We believe the future of healthcare depends on more predictable, evidence-aligned access pathways. Savvyn exists to make those pathways visible, actionable, and equitable—so when a technology becomes clinically meaningful, patients can actually receive it.
From Chaos to Clarity. Amplify Your Impact.
Meet Our Founder
Savvyn was founded by Catherine Del Vecchio Fitz, PhD, MSM, a scientist and operator who has spent her career advancing early cancer detection, precision oncology, and evidence-driven innovation in real-world settings.
Savvyn was built after seeing the same pattern repeatedly: even strong science can stall when evidence expectations are fragmented, unclear, or discovered too late across coverage decision-makers—delaying access for patients who could benefit.
Catherine holds a BA in Biology from Bowdoin College, completed a PhD in Cancer Biology and a Master of Science in Medicine at Stanford University, completed postdoctoral training at the Whitehead Institute at MIT, and is an alum of Harvard Business School’s Program for Leadership Development.
As a scientist and operator, she believes time is the most valuable resource we have—and builds systems that make work smarter, faster, and relentlessly efficient. Savvyn is a nod to being savvy—and just a little bit savage about efficiency.
